Biochemical markers of bone turnover in diagnosis of myeloma bone disease

American Journal of Hematology

Volumn 82, Issue 3, 2007, Pages 185-191

  Dizdar, Omer ^a   Barista, Ibrahim ^a   Kalyoncu, Umut ^a   Karadag, Omer ^a   Hascelik, Gulsen ^a   Cila, Aysenur ^a   Pinar, Asli ^a   Celik, Ismail ^a   Kars, Ayse ^a   Tekuzman, Gulten ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bone turnover markers; Macrophage inflammatory protein; Multiple myeloma; Osteopontin

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BETA 2 MICROGLOBULIN; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOPONTIN; PROTEIN PRECURSOR;

AGED; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; URINE LEVEL;

AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES; COLLAGEN TYPE I; FEMALE; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE MYELOMA; OSTEOPONTIN; PEPTIDES; PREDICTIVE VALUE OF TESTS;

EID: 33847615715     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20794     Document Type: Article

References (38)

1. Sirohi B, Powles R. Multiple myeloma. Lancet 2004;363:875-887.
2. Callander NS, Roodman GD. Myeloma bone disease. Semin Hematol 2001;38:276-285.
3. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc 1975;50:29-40.
4. Angtuaco EJ, Passas AB, Walker R, et al. Multiple myeloma: Clinical review and diagnostic imaging. Radiology 2004;231:11-23.
5. Abildgaard N, Brixen K, Kristensen JE, et al. Comparison of five biochemical markers of bone resorption in multiple myeloma: Elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003;120:235-242.
6. Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-1 collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 2002;69:37-42.
7. Nishizawa Y, Nakamura T, Ohata H, et al. Guidelines on the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Metab 2001;19:338-344.
8. Rosenbrock H, Seifert-Klauss V, Kaspar S, et al. Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med 2002;40:143-151.
9. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 2000;15:1526-1536.
10. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
11. Moulopoulos LA, Gika D, Anagnostopoulos A, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005;16:1824-1828.
12. Berenson JR, Lichtenstein A, Porter L, et al. for the Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-493.
13. Body JJ, Mancini I. Bisphosphonates for cancer patients: Why, how, and when? Support Care Cancer 2002;10:399-407.
14. Lecouvet FE, Malghem J, Michaux L, et al. Skeletal survey in advanced multiple myeloma: Radiographic versus MR imaging survey. Br J Haematol 1999;106:35-39.
15. Lecouvet FE, Vande Berg BC, Malghem J, Maldague BE. Magnetic resonance and computed tomography imaging in multiple myeloma. Semin Musculoskelet Radiol 2001;5:43-55.
16. Baur A, Stabler A, Nagel D, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334-1345.
17. Christenson RH. Biochemical markers of bone metabolism: An overview. Clin Biochem 1997;30:573-593.
18. Diamond T, Levy S, Smith A, et al. Non-invasive markers of bone turnover and plasma cytokines differ, in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance. Intern Med J 2001;31:272-278.
19. Alexandrakis MG, Passam FH, Malliaraki N, et al. Evaluation of bone disease in multiple myeloma: A correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients. Clin Chim Acta 2002;325:51-57.
20. Tamada T, Sone T, Tomomitsu T, et al. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: Diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 2001;19:45-51.
21. Woitge HW, Horn E, Keck AV, Auler B, Seibel MJ, Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 2001;47:686-693.
22. Jakob C. Zavrski I, Heider U, et al. Serum levels of carboxyterminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 2003;9:3047-3051.
23. Barille-Nion S, Barlogie B, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Hematol Am Soc Hematol Educ Program 2003:248-278.
24. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-2202.
25. Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jacob C, Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005;338:687-693.
26. Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-α (MIP-1 α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003;101:3568-3573.
27. Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-α is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-675.
28. Terpos E, Politou M, Szydlo R, et al. Serum levels of macrophage inflammatory protein-1 α (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003;123:106-109.
29. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986;83:8819-8823.
30. O'Regan A, Berman JS. Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:373-390.
31. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin-A possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990;87:4473-4475.
32. Standal T, Hjorth-Hansen H, Rasmussen T, et al. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004;89:174-182.
33. Abe M, Hiura K, Wilde J, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 2004;104:2484-2491.
34. Saeki Y, Mima T, Ishii T, et al. Enhanced production of osteopontin in multiple myeloma; Clinical and pathogenic implications. Br J Haematol 2003;123:263-270.
35. Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1 α is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003;120:53-55.
36. Cook G. Is long-term bisphosphonate administration associated with significantly increased circulating parathormone levels in patients with multiple myeloma? Eur J Endocrinol 2003;149:467-468.
37. Horiuchi T, Miyachi T, Arai T, et al. Raised plasma concentrations of parathyroid hormone related peptide in hypercalcemic multiple myeloma. Horm Metab Res 1997;29:469-471.
38. Ashcroft AJ, Davies FE, Morgan GJ. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 2003;4:284-292.